About dilution,Ceo owns close to 10% of this company, he will do everything it takes to minimalize diluting his own stake, they will announce Euro partner for Omidria real soon so that will bring in extra cash and vallue to our shares, they now have 20mil in cash and another 25 mil in august, that and growing omidria sales is enough to fund pipeline another year
AHUS and Igan are no large scale phase 3's
Maiby 40 patients or so due to rare disease,the U.S.,Euro and Asia market value for IgA nephropathy is +$5B
At the ERA-EDTA meeting in Mardrid last week European & Asian institutions asked Omeros to participate in the phase 3 trial, so worldwide partnerships are already beeing forged. Next in pipeline is Immunotherapy and their addiction program, if they , in time , need to dilute for those it would be few 100k shares,They don't need that much. OMS527 would be phase 1. Those are cheap. And by then price could be 50 to 75
After phase 1 revenue will be sufficient to fund the rest of the trials
Yesterday was a shareholders meeting, not a CC , so imo no transcripts or replay
Over 90% of the outstanding shares were represented at the meeting
Quote from someone who was there
"Meeting was insanely positive. FDA basically begged them to go fast track for IGAN. Also, removed criteria that would make it take 2-3yrs for drug to market. Could be on market in a year. With 150k potential patients in US, cost of 70-100k per patient annually. Addiction drug potential unreal. Would be largest drug ever to come to market, 1-2 years aways from trials. 906 for arthritis scaling up for clinical trials. DR D believes recognition of OMER only beginning, wanted to be biggest pharma out of NW ever, thinks that now is conservative."
We also reached $1B market cap, the minimum m. Cap for some large institutions before they start buying,also 20% still shorted, if price continue to climb we will see a few squeezes in the proces
So to scale things up,2 five billion dollar products about to be launched between year end and half 2018 , start of Immunotherapy and 906 trials very soon and start trials for the MASSIVE OMS527 next year will make this a multi year runner
Addiction drug potential is beyond believe,Would be largest drug ever to come to market, pre trials were promising
$1000 company within 5 year
Sorry for the gramatical errors, i'm flemmish
Gltu
News 
Market Data 
Discover 
